Strauss 2008.

Methods	randomized controlled trial, not placebo‐controlled
Participants	n = 74, cervical cancer (stage IIB‐IVA); concomitant treatment: radiochemotherapy
Interventions	drug = Epoetin beta dose = 150 IU/kg sc TIW hb‐target = 14‐15 g/dL planned ESA duration = 12 weeks
Outcomes	Primary: tumor control failures; secondary: progression‐free survival, overall response rate, relapses/metastases, overall survival, Hb change, QoL, safety
Notes	study number = 70404
Risk of bias
Bias	Authors' judgement	Support for judgement
Adequate sequence generation?	Unclear risk	patient randomization number will be generated by Roche
Allocation concealment?	Unclear risk	patient randomization numbers are to be allocated sequentially in the order in which the patients are enrolled